Advances in the treatment of IgA nephropathy
10.3760/cma.j.issn.1673-4408.2025.10.005
- VernacularTitle:IgA肾病的治疗进展
- Author:
Xiaohong ZHENG
1
;
Liping RONG
;
Xiaoyun JIANG
Author Information
1. 中山大学附属第一医院儿童肾脏风湿病中心,广州 510080
- Keywords:
IgA nephropathy;
Treatment;
Targeted therapy
- From:
International Journal of Pediatrics
2025;52(10):671-675
- CountryChina
- Language:Chinese
-
Abstract:
IgA nephropathy（IgAN）is the most common primary glomerular disease，characterized by the deposition of IgA in the glomerular mesangial area. IgAN is a progressive disease with a protracted and relapsing course. Approximately 50%~75% of adult IgAN patients experience renal function deterioration and eventually progress to end-stage kidney disease（ESKD）within 20 years after diagnosis. Among patients with onset in childhood，about 30% ultimately progress to ESKD after 20 years of long-term follow-up. In recent years，numerous studies have continuously explored important signaling pathways and key molecules in its pathogenesis. This review introduces the therapeutic advances in IgAN，aiming to provide better treatment options for clinicians.
